Thecompounds were then evaluated against glioma-initiating cells by monitoringthe level of CD44+; all the compounds decreased the level of CD44+.The results were further confirmed by in vivo experimentsin the brains of NOD-SCID mice, where compounds decreased the numberof glioma-initiating cells (Figure 53). The gene discussed is CD44; the disease is central nervous system cancer.